SEC Form 4 · accession 0001209191-17-013565
Insight Molecular Diagnostics Inc. · IMDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Lyndal K. Hesterberg
Officer — Sr VP, Research & Development
Period of report
Feb 17, 2017
Accepted (ET)
Feb 22, 2017 · 9:35 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001642380
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to Purchase Common StockF1 | $4.70 | Feb 17, 2017 | A | 14,400 | A | — | Feb 16, 2027 | Common Stock | 14,400 | 14,400 | D |
| Option to Purchase Common StockF2 | $4.05 | holding | — | — | — | — | Oct 31, 2026 | Common Stock | 125,000 | 125,000 | D |
| Option to Purchase Common StockF3 | $3.06 | holding | — | — | — | — | Feb 15, 2026 | Common Stock | 25,000 | 25,000 | D |
Explanation of responses
- F1One quarter of the options shall vest on February 16, 2018, subject to the completion of 12 months of continuous employment from the date of grant, and the balance shall vest in 36 monthly installments upon the completion of each month of continuous employment from the first anniversary of the date of grant.
- F2One quarter of the options shall vest on October 31, 2017, subject to the completion of 12 months of continuous employment from the date of grant on November 1, 2016, and the balance shall vest in 36 monthly installments upon the completion of each month of continuous employment from the first anniversary of the date of grant.
- F3One quarter of the options vested on February 15, 2017 and one quarter shall vest on February 15, 2018, and the balance shall vest upon the attainment of certain product development milestones, in each case depending upon continuous employment by the Company.